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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the effects of interventions for infantile seborrhoeic dermatitis in children from birth to 24 months of age.
B A C K G R O U N D
Description of the condition
Infantile seborrhoeic dermatitis (ISD) is a chronic, inflammatory
scaling skin condition, which typically causes redness and a patchy,
greasy scaling rash in babies and young children. It occurs on
skin areas where sebaceous glands are more frequent, that is, hair-
bearing and intertriginous areas (where the skin rubs together)
(Schwartz 2006). It frequently involves the scalp, where it is com-
monly referred to as cradle cap, because the hard scaly patches on
a red inflamed base can become thickened and confluent, resem-
bling a cap (Elish 2006). The scalp scale can be white or yellow.
Infantile seborrhoeic dermatitis can also affect the eyebrows, skin
behind the ears, diaper or nappy area, and skin creases of the neck
and under the arms. The appearance in the skin creases may be a
moist red rash rather than the yellowish scaly rash seen on the scalp
(eTG Complete 2013; Janniger 1993). The rash is not itchy or
painful, and usually, babies are oblivious to it, though it may cause
distress to parents. It is generally self-limiting, clearing by four to
six months of age in most cases (Elish 2006; Gelmetti 2011).
The condition occurs worldwide and affects all ethnic groups
(Palamaras 2012). It is very common, with the highest point preva-
lence - as reported in a large community-based study - observed
in the first three months of life (71.7%) and a high prevalence in
children under one year old (44.5%), reducing to 7.5% for the
age range 12 to 23 months (Foley 2003). The majority of these
cases are mild. Prevalence subsequently drops to < 1% in children
aged three years old (Foley 2003). One community-based cohort
study in Germany (Weisse 2012) documented the prevalence of
cradle cap as at 58.4% in the first year of life. However, this study
only reported doctor diagnosis of the condition, so may have un-
derreported the true prevalence. An Indian study retrospectively
reviewed outpatient paediatric dermatology clinic records and re-
ported that 52.4% of children presenting at < 1 year of age had
infantile seborrhoeic dermatitis (Sardana 2008).
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Given the considerable prevalence of the condition at one year of
age but low prevalence in children aged over two years, for the
purposes of this review, we use the term ’infantile’ loosely to refer
to children aged 0 to 24 months. There is some debate about the
degree to which ISD is the same entity as adult or adolescent seb-
orrhoeic dermatitis, with some authors defining them as separate
conditions bearing no relationship (eTG Complete 2013). Others
claim that it is the same disease (Schwartz 2006) or at least sim-
ilar enough to be able to extrapolate adult treatment data for the
paediatric population (Cohen 2004). One study (Mimouni 1995)
(with only 46% of participants followed up) cautiously suggested
a possible link between ISD and later seborrhoeic dermatitis, al-
though this conflicts with the results of another smaller retrospec-
tive cohort study (Menni 1989). Much of the literature on ISD
cites research in adult populations when discussing both causes
and treatments of the condition. There is similar debate about
whether ISD is part of a spectrum leading to atopic dermatitis
or psoriasis, a clinical syndrome presentation for several diseases,
or a separate condition (Alexopoulos 2013; Elish 2006; Gelmetti
2011; Moises-Alfaro 2002; Neville 1975; Williams 2005). Infan-
tile seborrhoeic dermatitis has been proposed as an umbrella term
encompassing several unrelated diseases, such as atopic dermatitis,
psoriasis, Langerhans’ cell histiocytosis, and erythroderma (red-
dening due to inflammatory skin disease) (Gelmetti 2011). More
traditionally, ISD is seen as a separate condition, with these other
disorders considered in the differential diagnosis, i.e., ISD may
share signs or symptoms with these other conditions, although it
is generally accepted that it can be difficult to distinguish ISD,
atopic dermatitis, and psoriasis in very young infants (Gelmetti
2011; Mimouni 1995). Other differential diagnoses include in-
tertrigo (rash in the folds of the body); contact dermatitis; and
multiple carboxylase deficiency, including biotinidase deficiency
(Gelmetti 2011).
The cause of ISD is not well understood, but several factors are
thought to play a role, involving an interplay between sebaceous
gland secretions, microflora metabolism, and individual suscep-
tibility (Ro 2005). One suggestion is that overactive sebaceous
glands on the skin of newborn babies, under the influence of cir-
culating maternal hormones, may secrete a greasy product that
causes old skin cells to stay adherent to the scalp instead of falling
off (New Zealand Dermatological Society 2012). It has also been
suggested that the presence of increased fatty acids causes excess
turnover of scalp cells leading to the flakes of ISD (Ro 2005). The
bimodal occurrence of seborrhoeic dermatitis in infancy under the
influence of maternal hormones then again in adolescence when
androgen production increases with puberty (Ro 2005; Schwartz
2006) supports a hormonal aetiology.
There is an established association between seborrhoeic dermati-
tis and the yeastMalassezia (formerly Pityrosporum) (Gupta 2004;
Zhang 2013). The yeast degrades sebum to release fatty acids,
consuming saturated fatty acids as a food source and leaving
the unsaturated fatty acids (Ro 2005). Recent studies have iden-
tified 10 species of Malassezia that can be present on the hu-
man head, the most common being M. restricta and M. globosa
(Ro 2005). Malassezia globosa and M. restricta were identified in
over 80% of seborrhoeic dermatitis patients of all ages attend-
ing an outpatient dermatology clinic (Zhang 2013). Malassezia
furfur has been cultured in significantly higher frequency from
children with ISD than children without the condition (Broberg
1995; Ruiz-Maldonado 1989). The response of ISD to antifun-
gals provides supportive evidence of the yeast playing a causative
role (Taieb 1990). In a small study, Ruiz-Maldonado cultured
Malassezia from 73% of infants with seborrhoeic dermatitis and
53% of controls (Ruiz-Maldonado 1989). This high prevalence
even in controls suggests that the condition is not due simply to
presence of the yeast, but that individual susceptibility plays a role.
In adults, as seborrhoeic dermatitis has been noted to occur even
in the presence of normal numbers of yeast, some authors argue
that an altered host response toMalassezia leads to the inflamma-
tory skin condition, rather than an overgrowth of the yeast itself
(Bergbrant 1989; Gupta 2004).
Severe generalised seborrhoeic dermatitis in children has been
noted to be uncommon in otherwise healthy children and can be a
presentation of underlying immunodeficiency. Desquamative ery-
throderma, previously known as Leiner’s disease (Prigent 2002), is
a rare condition involving severe ISD, which progresses to neonatal
erythroderma. It can present with associated immunodeficiency,
failure to thrive, and diarrhoea and is now thought to be a cuta-
neous expression of numerous underlying immunodeficiency dis-
orders, rather than a disease in itself (Gelmetti 2011). Children
with human t-cell leukaemia virus type 1 (HTLV-1) and human
immunodeficiency virus (HIV) infection have a higher incidence
of seborrhoeic dermatitis (Maloney 2004).
Historically, there has been some interest in the role of essential
fatty acids in ISD as the skin lesions seen in essential fatty acid
deficiency states are similar in appearance to ISD. Fatty acid defi-
ciencywas not present in infants with ISD in one study (Erlichman
1981). However, Tollesson and colleagues have described an al-
tered pattern of serum essential fatty acids in children with ISD,
which resolves in parallel with clinical resolution of the condi-
tion at any age (Tollesson 1993). This could in fact be related to
Malassezia metabolism of fatty acids (Ro 2005).
Description of the intervention
While ISD is generally considered a benign and self-limiting con-
dition, for which no treatment may be required (Arora 2007),
many treatments have been proposed and are commercially avail-
able for it. Several treatments have been studied for adult sebor-
rhoeic dermatitis (Kastarinen 2014). These include anti-inflam-
matory agents (e.g., topical steroids and calcineurin inhibitors);
keratolytics (peeling agents) to soften and remove scale (e.g., sali-
cylic acid, tar, zinc); antifungals to reduce yeast (e.g., ketoconazole,
selenium sulfide); and alternative therapies, which may have mul-
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tiple mechanisms of action (e.g., tea tree oil shampoo) (Schwartz
2006).
The role of treatments specifically for infantile seborrhoeic der-
matitis is less clear. Topical ketoconazole (an antifungal) has been
shown to be safe in infants, with minimal systemic absorption
detected (Brodell 1998; Taieb 1990). Several authors recommend
application of emollient creams or mineral or vegetable oils (e.g.,
olive oil, borage oil) to soften scale, with or without frequent
washing with baby shampoo or medicated shampoo to lift scale,
followed by brushing to mechanically remove scale (Elish 2006;
Gelmetti 2011; Smoker 2007). Anti-inflammatories, such as top-
ical hydrocortisone cream, have also been recommended for ISD,
though concerns have been raised about side-effects (Arora 2007;
Wannanukul 2004). Historically, biotin has also been postulated
as a treatment, because similar scalp lesions to ISD are seen as part
of biotinidase deficiency conditions (Erlichman 1981; Gelmetti
2011; Keipert 1976). Additionally, complementary and alterna-
tive medicines are also used to treat ISD. Recently, licochalcone
(extracted from Glycyrrheiza inflata) has been studied as a treat-
ment for ISD (Wananukul 2012).
Concerns have been raised about the use of olive oil to soften
and lift scale, as it promotes a favourable environment for the
yeastMalassezia furfur to proliferate and may theoretically worsen
the condition (Siegfried 2012; Smoker 2007). Concerns have also
been raised about keratolytics, such as salicylic acid, which are
recommended by some (eTG Complete 2013; Smoker 2007), be-
cause of risks of systemic absorption, reportedly the cause of sali-
cylate toxicity in infants after topical application for another con-
dition (Abdel-Magid 1994). Similarly, selenium sulphide, which
is used to treat other conditions (Chen 2010), has been reported
to cause scalp discolouration (Fitzgerald 1997; Gilbertson 2012),
and concerns have been raised about the dangers of systemic ab-
sorption (Gelmetti 2011). Additionally, some proposed treatments
may have low acceptability for some cultural groups. For example,
in people of African-American or African ethnicity with tightly
curled hair that requires a lot of styling after washing, frequent
hair-washing may be recommended despite indications that low
hair-washing frequency is not associatedwith seborrhoeic dermati-
tis in African-American girls (Rucker Wright 2010).
How the intervention might work
Proposed treatments for infantile seborrhoeic dermatitis include
topical antifungals aimed at reducing the yeast thought to be in-
volved in the pathogenesis of the condition and known to be ef-
fective in treating adult seborrhoeic dermatitis. Some other treat-
ments, such as topical steroids, aim to reduce inflammation. Other
treatments rely on a mechanical effect, aiming to soften then lift
away scale. These treatments include application of oils or ker-
atolytics, followed by washing and brushing, or simply frequent
washing with baby shampoos, followed by brushing.
Several studies of adult seborrhoeic dermatitis have noted topical
steroids and topical antifungals (particularly ketoconazole) have
both been effective, but they suggested that ketoconazole was bet-
ter at preventing recurrences (Cohen 2004). It is unclear whether
evidence for adult seborrhoeic dermatitis can indeed be applied to
infantile seborrhoeic dermatitis. Treatments for adults with seb-
orrhoeic dermatitis are the subject of two Cochrane publications:
a published protocol, ’Interventions for seborrhoeic dermatitis’
(Okokon 2009), and a published systematic review, ’Topical anti-
inflammatory agents for seborrhoeic dermatitis of the face or scalp’
(Kastarinen 2014).
Why it is important to do this review
While the condition is generally self-limiting and benign, causing
no discomfort to the infant, it can cause considerable distress for
parents. The myriad of commercially available and home reme-
dies used by parents is evidence for the importance placed on in-
fantile seborrhoeic dermatitis. Importantly, some of the currently
used therapies may be harmful, as outlined above, so this review
is needed to prevent harm to infants treated needlessly with those
agents. Additionally, there has been no previous systematic review
that we are aware of that specifically addresses seborrhoeic der-
matitis in infants and children.
O B J E C T I V E S
To assess the effects of interventions for infantile seborrhoeic der-
matitis in children from birth to 24 months of age.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Only randomised controlled trials (RCTs) of interventions for in-
fantile seborrhoeic dermatitis.
Types of participants
All children from birth to 24 months diagnosed with infantile
seborrhoeic dermatitis or cradle cap, based on clinical diagnosis
by a healthcare practitioner.
3Interventions for infantile seborrhoeic dermatitis (including cradle cap) (Protocol)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Types of interventions
All interventions, whether behavioural or pharmacological (in-
cluding complementary and alternative medicines). We will com-
pare the following:
1. any treatment versus no treatment or placebo; or
2. comparison of two or more treatments or combinations of
treatments.
We will also group analyses into types of treatment (for example,
anti-inflammatory agents, keratolytics, antifungals, or alternative
therapies).
Types of outcome measures
We will include trials in the review even if they do not report
relevant outcomes, but we will not include these trials in a meta-
analysis. We will give reasons for exclusion from analysis.
Primary outcomes
1. Change in severity score from baseline to end of study
(described by measures of surface area, redness, crust, or scale)
(continuous outcome).
2. Percentage of persons treated who develop adverse effects or
intolerance to treatment (dichotomous outcome).
Secondary outcomes
1. Improvement in quality of life (QoL) as reported by
parents: either continuous (score on QoL scale) or dichotomous
(improved or not).
If studies use different scales of severity or quality of life, we will
either standardise these scales (so that they can be combined in a
meta-analysis) or describe the outcomes narratively.
Search methods for identification of studies
We aim to identify all relevant RCTs regardless of language or pub-
lication status (published, unpublished, in press, or in progress).
Electronic searches
We will search the following databases for relevant trials:
• the Cochrane Skin Group Specialised Register;
• the Cochrane Central Register of Controlled Trials
(CENTRAL) in The Cochrane Library;
• MEDLINE via Ovid (from 1946);
• Embase via Ovid (from 1974); and
• LILACS (Latin American and Caribbean Health Science
Information database, from 1982).
We have devised a draft search strategy for RCTs for MEDLINE
(Ovid), which is displayed in Appendix 1. This will be used as the
basis for search strategies for the other databases listed.
Trials registers
We will search the following trials registers:
• The metaRegister of Controlled Trials (www.controlled-
trials.com).
• The US National Institutes of Health Ongoing Trials
Register (www.clinicaltrials.gov).
• The Australian New Zealand Clinical Trials Registry (
www.anzctr.org.au).
• The World Health Organization International Clinical
Trials Registry platform (www.who.int/trialsearch).
• The EU Clinical Trials Register (
www.clinicaltrialsregister.eu/).
Searching other resources
References from included studies
We will check the bibliographies of included studies for further
references to relevant trials.
Unpublished literature
We will search unpublished RCTs and grey literature via web
search engines and correspondence with authors and pharmaceu-
tical companies.
Adverse effects
We will not perform a separate search for adverse effects of inter-
ventions used for the treatment of infantile seborrhoeic dermati-
tis. We will consider adverse effects and side-effects described in
included studies only.
Data collection and analysis
Some parts of themethods section of this protocol uses text thatwas orig-
inally published in another Cochrane protocol on seborrhoeic dermati-
tis occurring in adolescents and adults: Okokon EO,Oyo-Ita A, Chosi-
dow O. Interventions for seborrhoeic dermatitis (Protocol). Cochrane
Database of Systematic Reviews 2009, Issue 4. Art. No.: CD008138.
DOI: 10.1002/14651858.CD008138 (Okokon 2009).
We plan to include at least one ’Summary of findings’ table in
our review. In this, we will summarise the primary outcomes for
the most important comparison. If we feel there are several major
comparisons or that our findings need to be summarised for dif-
ferent populations, we will include further ’Summary of findings’
tables.
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Selection of studies
We will identify titles and abstracts that have been classed as ran-
domised controlled trials on infantile seborrhoeic dermatitis (ISD)
and assess if the studies meet the inclusion criteria. We will re-
trieve the full text of these studies and references that could not
be assessed based on title or abstract alone. Two authors (AV and
PJM) will independently carry out selection of studies for inclu-
sion and resolve disagreement through discussion and consensus
and, if necessary, further discussion with a third author (MVD).
We will make attempts to obtain translations of studies not pub-
lished in English.We will highlight excluded studies and state why
we excluded these studies. If we find multiple reports of the same
study, we will collate these so that the study, not the report, is the
unit of analysis (Chandler 2013).
Data extraction and management
We will adapt the Cochrane Skin Group data extraction form for
our review. PJM and AV will perform data extraction indepen-
dently and make entries onto the form. A third author, MVD, will
resolve any disagreements. A ’Characteristics of included studies’
table for each study will include details of participant demograph-
ics, the type of intervention and comparators, outcomes reported,
and the study design.
AVwill check the data and enter it into RevMan (ReviewManager
(RevMan) 2014).
Wewill use data as presented in the available publications, calculate
necessary data from other reported parameters (such as P values
and confidence intervals), or request additional data from study
authors.
We will compare direction and magnitude of effects reported by
studies with how they appear in the review (Chandler 2013).
Assessment of risk of bias in included studies
Two authors (AV and PJM) will independently enter characteris-
tics of studies and ’Risk of bias’ assessments into appropriate ta-
bles, with any disagreement resolved by consensus and, if neces-
sary, discussion with a third author (MVD).
We will assess the risk of bias in the following domains as outlined
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011):
• method of random sequence generation - we will consider
this adequate if generated centrally by means other than the
immediate investigator;
• method of allocation concealment - we will consider this
adequate if investigators or participants could not be foresee
assignment;
• blinding of participants or carers, health professionals, or
outcome assessors and whether the measurement of the outcome
was likely to be affected if outcome assessors were not blinded;
• attrition bias - loss to follow up and whether intention-to-
treat analysis was used;
• selective reporting; and
• other bias - for example, systemic contamination or carry-
over effects with split lesion studies, baseline imbalance.
We will assess each item as low risk, high risk, or unclear risk if
insufficient information is available to adequately assess the risk
and summarise the results in a ’Risk of bias’ table.
Measures of treatment effect
For dichotomous outcomes, wewill express the results as risk ratios
(RR) with a 95% confidence interval (CI) and as a number needed
to treat where appropriate with a 95% CI and the baseline risk
to which it applies. For continuous outcomes, we will express the
results as mean differences (MD) with standard deviations (SD)
when the same outcome scales are used, or as standardised mean
differences (SMD) with SD when different scales are used in the
pooled trials. Where different scales are used and those studies are
combined, we will ensure the direction of the scale is the same for
each study and report if we have had to reverse the direction to
enable the studies to be combined.
Unit of analysis issues
Where there are multiple interventions within a trial, we will use
pair-wise comparisons of two interventions or intervention ver-
sus placebo. We will avoid double-counting of placebo groups by
splitting the placebo group participants evenly over the compar-
isons, as per the Cochrane Handbook for Systematic Reviews of In-
terventions (Higgins 2011).
In the case of cross-over trials, we will only use the first comparison
to avoid contamination due to carry-over effects, unless the risk of
these has been assessed to be low, in which case, we will consider
each of the treatment cycles for the analysis. We will analyse these
combined treatment cycles as in a parallel group design, taking
into account that this may underestimate the true effect. We will
discuss the impact on the overall estimate in the discussion of the
review. We will only pool results of studies of the same design.
We will analyse studies involving different interventions for dif-
ferent body parts on the same individual by considering each body
part as the unit of analysis (Higgins 2011). We will evaluate stud-
ies involving different interventions for different parts of the same
lesion for potential contamination effects, and if this is too high,
we will not include the study in meta-analysis and we will provide
reasons for our decision. If we assess the risk as low, we will analyse
such studies in the same way as a cross-over trial (Higgins 2011).
In cluster-randomised trials where the unit of analysis is not the
same as the unit of randomisation, we will use analyses from the
trials that adjust for clustering. If there are trials that do not adjust
for clustering, we will attempt to account for the clustering in our
analysis. This may be done through a number of methods ideally
based on a direct estimate of the required effect measure, as stated
in the Cochrane Handbook for Systematic Reviews of Interventions,
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section 16.3.3 (Higgins 2011). We will use the generic inverse
variance method in RevMan (Review Manager (RevMan) 2014)
to pool data from cluster-randomised trials (Higgins 2011).
Dealing with missing data
We will attempt to contact authors of studies with missing data
to obtain sufficient data for analysis and pooling. If insufficient
information is available to enable ’Risk of bias’ assessment, we will
classify these studies as having either high risk (if it is likely that the
missing information actually refers to absence of an appropriate
study process) or unclear risk (if the absence of information could
be a reporting issue). We will justify in the ’Risk of bias’ table how
we came to our decision.
If insufficient information is available for outcome data, we will
perform an intention-to-treat (ITT) analysis. In the ITT analysis,
we will analyse all participants in the group to which they were
randomised, regardless of whether they changed over to another
group.
In a sensitivity analysis, we will assess the impact of missing
data and assumptions made on the overall estimate of effect (see
Sensitivity analysis).
Assessment of heterogeneity
We will assess clinical heterogeneity of studies by examining par-
ticipants, interventions, and outcomes in each study. If there is
no face value heterogeneity (e.g., clearly different populations),
we will perform a Chi² test with significance set at a P value of
0.10. We will assess statistical heterogeneity using I² statistic and
consider heterogeneity significant where I² statistic is greater than
50%. Where statistical heterogeneity is > 80%, we will not per-
form a meta-analysis, but summarise studies individually.
Thresholds for the interpretation of the I² statistic can be mis-
leading. We will use the following rough guide to interpretation
(Higgins 2011):
• 0% to 40% might not be important;
• 30% to 60% may represent moderate heterogeneity;
• 50% to 90% may represent substantial heterogeneity; and
• 75% to 100% may represent considerable heterogeneity.
Assessment of reporting biases
If we find more than 10 RCTs for an outcome, we will draw a
funnel plot to assess the risk of publication bias, which we will
inspect for asymmetry.
Data synthesis
We will use the Mantel-Haenszel method for pooling dichoto-
mous data. When pooling continuous data, we will use the mean
difference (MD) when outcomes are measured on the same scale
or a standardised mean difference (SMD) when different scales are
used (Higgins 2011). In the absence of clinical and statistical het-
erogeneity, we will pool data using a fixed-effect model (Higgins
2011). If significant heterogeneity is present, we will either use a
random-effects model, or we will not pool the studies. We will not
pool cross-over studies and split body part study designs with par-
allel studies. Where it is not possible to perform a meta-analysis,
we will summarise data from individual studies. Where it is not
possible to perform a meta-analysis, we will summarise data from
individual studies. We will regard a P value of </= 0.05 as statisti-
cally significant. We will interpret a higher P value as a finding of
uncertainty, which is not the same as a lack of effect.
We will use the Grading of Recommendations Assessment, De-
velopment and Evaluation (GRADE) system to assess the quality
of the evidence for each outcome.
Subgroup analysis and investigation of heterogeneity
If substantial clinical or statistical heterogeneity exists amongst the
included studies, we will explore the reasons for this by examining
factors such as participant age, duration of the rash, and study
design.
Where adequate information is given, we will perform further
subgroup analyses of infants less than six months old and greater
than or equal to six months old.
Sensitivity analysis
If we obtain sufficient evidence, we plan to conduct sensitivity
analyses to explore the effects of risk of bias, assessing the effect of
excluding poor-quality studies (those with a moderate or high risk
of bias) and the effect of missing data (by comparing on-treatment
and ITT analyses) on the overall estimate of effect.
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A P P E N D I C E S
Appendix 1. MEDLINE (Ovid) draft search strategy
1. cradle cap.ti,ab.
2. crusta lactea.ti,ab.
3. milk crust.ti,ab.
4. honeycomb disease.ti,ab.
5. or/1-4
6. pityriasis capitis.ti,ab.
7. seborrhea.ti,ab.
8. Dermatitis, Seborrheic/
9. seborrh$ dermatitis.ti,ab.
10. scalp dermatos$.ti,ab.
11. Scalp Dermatoses/
12. scalp dermatitis.ti,ab.
13. scalp eczema.ti,ab.
14. seborrh$ eczema.ti,ab.
15. or/6-14
16. neonatal.mp.
17. infant$.mp.
18. exp Infant/
19. 16 or 17 or 18
20. 15 and 19
21. 5 or 20
22. randomized controlled trial.pt.
23. controlled clinical trial.pt.
24. randomized.ab.
25. placebo.ab.
26. clinical trials as topic.sh.
27. randomly.ab.
28. trial.ti.
29. 22 or 23 or 24 or 25 or 26 or 27 or 28
30. exp animals/ not humans.sh.
31. 29 not 30
32. 21 and 31
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